[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chronic-kidney-disease-requiring-chronic-dialysis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chronic-kidney-disease-requiring-chronic-dialysis":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,12,0,[8,47,60,87,117,140,167,203,229,254,280,306],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100053390","phase-2-a-study-to-evaluate-safety-tolerability-and-efficacy-of-ap306-at-fixed-doses-in-dialysis-participants-with-hyperphosphatemia-100053390",false,"NCT06712654","A Study to Evaluate Safety, Tolerability and Efficacy of AP306 at Fixed Doses in Dialysis Participants With Hyperphosphatemia","A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety, Tolerability, and Serum Phosphate Lowering Effect of Fixed Dose AP306 in Participants With Hyperphosphatemia Receiving Maintenance Hemodialysis","Important Inclusion Criteria:\n\n* Signs a written informed consent form (ICF) and is willing to comply with all study requirements in the study\n* Receiving a stable hemodialysis (including hemodialysis, hemodiafiltration, and hemoadsorption) regimen, which is defined as a frequency of three times per week for at least 12 weeks before signing the ICF, and does not plan to change in the study\n* Who has a blood phosphate level within the study-required range\n* Who has a dialysis adequacy, assessed by single pooled Kt\u002FV (SpKt\u002FV, estimated with blood urea) ≥1.20, at screening or any documented value ≥1.20 within 12 weeks prior to signing the ICF\n* If the participant is receiving etelcalcetide, their doses must be unchanged for at least 4 weeks prior to signing the ICF\n* If the participant is receiving any of the following therapies, their doses are stable for at least 14 days prior to signing the ICF: phosphate-lowering products other than tenapanor or phosphate binders, active vitamin D and analogs, cinacalcet, calcitonin, and P-glycoprotein inhibitors\n* Agreement to use highly effective contraception for women of childbearing potentially and non-sterile sexually active males throughout the study and for 90 days after the final dose of study drug\n\nImportant Exclusion Criteria:\n\n* Pregnant or breastfeeding\n* Scheduled for a living donor kidney transplant in the next 6 months, planned change to peritoneal dialysis or home hemodialysis in the study; planned relocation to another dialysis center in the study\n* Any history of a non-pharmacological parathyroid intervention within 6 months prior to the ICF sign off, or planned parathyroid intervention in the study\n* Blood calcium or blood intact parathyroid hormone abnormality\n* Adequate organ and bone marrow function\n* Acute hepatitis or significant chronic liver disease\n* Any clinically significant GI disorders within 4 weeks prior to signing the ICF; or any history of gastrectomy; or any GI tract surgery (excluding appendectomy and polypectomy), within 12 weeks of signing the ICF\n* Uncontrolled hypertension\n* Hospitalization for cardiac or cardiocerebrovascular disease within 24 weeks prior to signing the ICF\n* Significant abnormalities of QT interval and heart rhythm on an electrocardiograph (ECG) test\n* Any clinically significant active infection or infestation or any treatment with systemic antimicrobial treatment within 2 weeks prior to signing the ICF\n* History or presence of malignancy within 3 years prior to signing the ICF, except basal cell skin cancer, in-situ carcinoma of the cervix, and in-situ prostate cancer\n* Taking moderate or strong cytochrome P450 (CYP) 3A inhibitors within 2 weeks or 5 half-lives, whichever is longer, prior to signing the ICF (topical use is allowed)\n* Treatment with any investigational medication or medical device within 30 days prior to signing the ICF\n* Life expectancy less than 12 months","ALL","18 Years",{"count":19,"type":20},168,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","This study is being conducted to characterize the safety, tolerability, and efficacy of AP306 at fixed doses in adults with hyperphosphatemia receiving maintenance hemodialysis.",[26,27,28],"Hyperphosphatemia","Chronic Kidney Disease Requiring Chronic Dialysis","End Stage Renal Disease on Dialysis",[30,31,32,33],"AP306","AP-306","EOS789","pan-phosphate transporter inhibitor","RECRUITING","2026-07-10",{"date":37,"type":38},"2026-07-13","ACTUAL",{"date":40,"type":38},"2026-06-01",{"date":42,"type":20},"2027-03-31",{"name":44,"class":45},"R1 Therapeutics","INDUSTRY",31,{"id":48,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":21,"phases":50,"briefSummary":24,"conditions":51,"keywords":52,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":54,"startDateStruct":56,"completionDateStruct":57,"leadSponsor":58,"locationsCount":59},"100570854",{"count":19,"type":20},[23],[26,27,28],[30,31,32,33],"2026-06-26",{"date":55,"type":38},"2026-06-29",{"date":40,"type":38},{"date":42,"type":20},{"name":44,"class":45},30,{"id":61,"slug":62,"hasResults":11,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":4,"eligibilityCriteria":66,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":67,"targetDuration":4,"studyType":69,"phases":4,"briefSummary":70,"conditions":71,"keywords":73,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":86},"100417895","fluid-intake-after-hemodialysis-100417895","NCT04721652","Fluid Intake After Hemodialysis","Fluid Intake After Hemodialysis: Investigating the Relationship Between Time and Weight Gain During the Interdialytic Interval","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Thrice weekly maintenance hemodialysis\n* Willing and able to provide written informed consent\n\nExclusion Criteria:\n\n* Diabetes Mellitus\n* Residual Urinary Volume \\> 500 ml\u002Fday\n* Being able to self-monitor one's body weight and blood pressure",{"count":68,"type":20},20,"OBSERVATIONAL","Interdialytic weight gain determines how much fluid (ultrafiltration) has to be removed during each hemodialysis session. High ultrafiltration volumes stress the organism and lead to a higher risk of death. Thirst is the main driving factor of interdialytic weight gain, and thirst is mainly driven by salt intake, molecules that increase blood tonicity (such as sugar in diabetics) and fluid loss (such as in dehydration and blood loss). It has been speculated that fluid loss during hemodialysis could increase the sense of thirst immediately following dialysis, but this statement requires further evidence.",[27,72],"Interdialytic Weight Gain",[74,72,75],"Hemodialysis","Thirst","2026-04-28",{"date":78,"type":38},"2026-05-04",{"date":80,"type":38},"2021-02-25",{"date":82,"type":20},"2026-12-31",{"name":84,"class":85},"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","OTHER",2,{"id":88,"slug":89,"hasResults":11,"nctId":90,"briefTitle":91,"officialTitle":91,"acronym":92,"eligibilityCriteria":93,"healthyVolunteers":94,"sex":16,"minAge":17,"maxAge":95,"enrollmentInfo":96,"targetDuration":4,"studyType":69,"phases":4,"briefSummary":98,"conditions":99,"keywords":101,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":116},"100564926","impact-of-kidney-failure-on-the-regulation-of-humoral-response-to-vaccination-100564926","NCT06635525","Impact Of Kidney Failure On The Regulation Of Humoral Response To Vaccination","Tfh-CKD","Inclusion Criteria:\n\n* Age between 18 and 70 years\n* Patients undergoing thrice-weekly hemodialysis \u002F peritoneal dialysis for at least 3 months OR healthy individuals without a history of renal insufficiency\n* Subjects eligible to receive a seasonal influenza vaccine\n* Signed informed consent for participation in the study\n\nExclusion Criteria:\n\n* Recent influenza infection (clinically resolved less than 3 months ago).\n* Administration of immunosuppressive drugs in the two weeks prior to vaccination.\n* Administration of another vaccine in the three weeks prior to enrollment (co-administration of other vaccines with those under study does not contraindicate participation).\n* Systemic infection clinically resolved less than two weeks before enrollment.",true,"70 Years",{"count":97,"type":20},146,"The aim of this observational study is to determine if and how kidney failure affects the development of protective immune responses following vaccination in patients on chronic dialysis.\n\nResearchers will compare the effectiveness of the influenza vaccine in inducing protective antibodies between hemodialysis patients and subjects without chronic kidney disease.\n\nParticipants will:\n\n* Be enrolled at the time of influenza vaccination\n* Visit the clinic at 7, 14, 30, 60, and 120 days after vaccination\n* Be asked to provide relevant clinical information and a blood sample at each visit",[27,100],"Vaccine Response",[102,103,104,74,105,106],"Vaccine","Influenza","Chronic Kidney Disease","Peritoneal dialysis","Humoral Response","2026-03-25",{"date":109,"type":38},"2026-03-30",{"date":111,"type":38},"2024-10-16",{"date":113,"type":20},"2026-07",{"name":115,"class":85},"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico",3,{"id":118,"slug":119,"hasResults":11,"nctId":120,"briefTitle":121,"officialTitle":121,"acronym":122,"eligibilityCriteria":123,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":124,"targetDuration":4,"studyType":69,"phases":4,"briefSummary":126,"conditions":127,"keywords":128,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":139},"100618540","impact-of-dialysis-on-sexuality-100618540","NCT07332949","Impact of Dialysis on Sexuality.","SEXODIA","Inclusion Criteria:\n\n* Patient \\> 18 years,\n* Treated with chronic dialysis (hemodialysis or peritoneal dialysis) for at least 6 months.\n\nExclusion Criteria:\n\n* Major cognitive or psychiatric disorders that make understanding or completing the questionnaire difficult.\n* General health condition not allowing participation without significant discomfort or excessive fatigue.\n* Opposition by the patient.",{"count":125,"type":20},100,"Sexuality is an essential dimension of quality of life and is frequently impaired in patients with end-stage chronic kidney disease undergoing hemodialysis. Sexual dysfunctions-including erectile dysfunction, reduced sexual desire, and difficulties with arousal or orgasm-are highly prevalent in this population. These disorders have multifactorial origins, involving hormonal disturbances, comorbidities, treatment-related side effects, chronic fatigue, and the psychological and relational impact of long-term illness.\n\nDespite their frequency, sexual health issues are rarely addressed in routine dialysis care. This is largely due to time constraints during consultations, insufficient training of healthcare professionals, and persistent social and cultural taboos. In addition, the existing scientific literature remains limited, often outdated, and predominantly focused on male patients. Data concerning women, sexual diversity, body image, and couple-related aspects are scarce. Standard kidney disease-specific quality-of-life instruments, such as the KDQOL questionnaire, provide only a minimal assessment of sexuality, with a single item related to sexual desire.\n\nThe aim of this study is to provide a contemporary and comprehensive assessment of the impact of dialysis on sexual quality of life. By documenting sexual function and sexual complaints in patients undergoing dialysis, this study seeks to improve understanding of patients' experiences and to facilitate communication between patients and healthcare professionals. Ultimately, the findings are intended to support better integration of sexual health into routine nephrology care and to contribute to improved clinical practices in the field of sexual health.\n\nThis study is designed as a cross-sectional survey conducted among patients undergoing dialysis at the Groupe Hospitalier Privé Ambroise Paré-Hartmann in the Paris area. Eligible patients are informed about the study during a dialysis session by a healthcare professional (dialysis nurse, nephrologist, or physiotherapist specialized in sexology). Participants complete a self-administered questionnaire during their dialysis session, including the Male Sexual Health Questionnaire (MSHQ) for men and the Female Sexual Function Index (FSFI) for women. Additional questions addressing medical history and body image perception are included. The estimated completion time for the questionnaire is approximately 20 minutes.",[27],[74,105,129],"Sexuality","2026-02-03",{"date":132,"type":38},"2026-02-04",{"date":134,"type":38},"2026-01-30",{"date":136,"type":20},"2027-01-30",{"name":138,"class":85},"CMC Ambroise Paré",1,{"id":141,"slug":142,"hasResults":11,"nctId":143,"briefTitle":144,"officialTitle":144,"acronym":145,"eligibilityCriteria":146,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":147,"targetDuration":4,"studyType":21,"phases":149,"briefSummary":151,"conditions":152,"keywords":154,"overallStatus":157,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":139},"100623135","the-intravenous-amino-acid-therapy-for-vascular-rigidity-in-end-stage-renal-disease-100623135","NCT07392697","The Intravenous Amino Acid Therapy for Vascular Rigidity in End Stage Renal Disease","NASCAR","Inclusion Criteria:\n\n* Age ≥18 years.\n* Diagnosis of end-stage renal disease (ESRD) and undergoing maintenance hemodialysis (HD) or online hemodiafiltration (HDF).\n* On a stable dialysis regimen for a minimum of 90 consecutive days prior to enrollment.\n* Serum albumin level ≥30 g\u002FL.\n* Documented dialysis adequacy: single-pool Kt\u002FV (spKt\u002FV) \\> 1.2.\n* Able to understand study procedures and provide written informed consent.\n\nExclusion Criteria:\n\n* Administration of parenteral amino acids or intravenous nutrition within the past 90 days.\n* Severe hypertension (e.g., SBP \\>180 mmHg despite antihypertensive therapy).\n* Advanced liver disease classified as Child-Pugh class C.\n* Diagnosis of active malignancy or cancer treatment within the last 5 years.\n* Current participation in another interventional study or within the past 30 days.\n* Pregnant or breastfeeding women.\n* Psychiatric or cognitive impairment that interferes with informed consent or study compliance.\n* Life expectancy \\\u003C12 months due to unrelated comorbidities.",{"count":148,"type":20},120,[150],"NA","The goal of this study is to learn if giving amino acids through the dialysis machine can help protect the blood vessels and heart in people with kidney failure. Patients on dialysis often have problems with stiff blood vessels, which increases their risk of heart attacks, strokes, and other cardiovascular diseases. A chemical change called carbamylation is thought to make blood vessels age and stiffen faster. Amino acids may block this process and improve blood vessel health.\n\nThe main questions are:\n\n* Does amino acid treatment reduce the risk of death in dialysis patients?\n* Does it improve the health of the heart and blood vessels?\n* What side effects or medical problems happen when patients receive amino acids during dialysis?\n\nIn this study:\n\n* Participants will be randomly assigned to receive either amino acids (Synthamin 9®) or a placebo (saline).\n* The infusion (250 ml) will be given twice a week during dialysis sessions for 12 months.\n* After 12 months of treatment, patients will be followed for another 6 months.\n\nDuring the study, patients will:\n\n* Have regular blood tests to measure markers of blood vessel health, inflammation, and protein carbamylation.\n* Undergo heart and vessel tests, including echocardiography, CT scans, and pulse wave velocity measurements.\n* Complete quality-of-life questionnaires about symptoms and daily living.\n\nBy comparing the amino acid group with the placebo group, researchers will see whether amino acid therapy can make dialysis patients live longer and have healthier hearts and blood vessels.",[27,153],"Cardiovascular Calcification",[155,156],"carbamylation","chronic kidney disease","NOT_YET_RECRUITING","2026-01-29",{"date":160,"type":38},"2026-02-06",{"date":162,"type":20},"2026-02-01",{"date":164,"type":20},"2028-11-01",{"name":166,"class":85},"Haukeland University Hospital",{"id":168,"slug":169,"hasResults":11,"nctId":170,"briefTitle":171,"officialTitle":172,"acronym":173,"eligibilityCriteria":174,"healthyVolunteers":11,"sex":16,"minAge":175,"maxAge":4,"enrollmentInfo":176,"targetDuration":4,"studyType":21,"phases":178,"briefSummary":179,"conditions":180,"keywords":187,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":195,"lastUpdatePostDateStruct":196,"startDateStruct":198,"completionDateStruct":200,"leadSponsor":202,"locationsCount":139},"100566830","dialysis-with-expanded-solute-removal-100566830","NCT06660277","DIALysis With EXpanded Solute Removal","DIALysis With EXpanded Solute Removal (DIALEX): A Large, Simple Randomized Trial to Evaluate the Major Health Effects of Expanded Versus Conventional Hemodialysis.","DIALEX","Inclusion Criteria: Inclusion requires that all the following are present:\n\n1. One of:\n\n   1. Age 60 years or older; or\n   2. Age 45 to 59 years with a history of diabetes mellitus (Type 1 or Type 2) regardless of current glycemic status; and\n2. Receiving any form of dialysis regularly for the previous 90 days; and\n3. Currently receiving HD in-centre (main or satellite unit) 3 or more times per week; and\n4. A valid provincial or territorial health insurance card number.\n\nExclusion Criteria: Patients are ineligible if they meet any of the following criteria:\n\n1. Not appropriate for this study in the opinion of the treating nephrologist or dialysis nurse practitioner due to any of:\n\n   1. Known or anticipated intolerance to the Nipro Elisio HX dialyzer; or\n   2. Planned to receive HDF; or\n   3. Planned to receive nocturnal HD; or\n   4. Anticipated to discontinue in-centre HD in the next 3 months for any reason (examples: palliation, transplantation, home dialysis, recovery of kidney function, death, others); or\n   5. Anticipated severe non-adherence to the frequency or duration of prescribed dialysis treatment; or\n   6. An overriding clinical preference for expanded HD (i.e., dialysis with the Elisio HX or other comparable dialyzer, such as Baxter TheranovaTM); or\n   7. Another medical, psychosocial, or logistical reason; or\n2. Enrolled in another clinical trial that explicitly prohibits concurrent participation in other clinical trials or that would substantially interfere with adherence to the DIALEX procedures (note that DIALEX otherwise permits concurrent participation in other trials); or\n3. Previously enrolled in this trial; or\n4. Declined participation.","45 Years",{"count":177,"type":20},4800,[150],"The goal of this clinical trial is to evaluate the health effects of expanded hemodialysis in patients receiving hemodialysis. The main question it aims to answer is:\n\n1\\) Does expanded hemodialysis reduce the risk of death from any cause?\n\nResearchers will compare expanded hemodialysis to conventional hemodialysis (the treatment currently used for the majority of patients receiving hemodialysis) to see if expanded hemodialysis works to improve patient outcomes.\n\nParticipants will continue to receive their regularly scheduled hemodialysis treatments using either a super high-flux\u002Fexpanded dialysis filter or a high-flux\u002Fconventional dialysis filter. All other aspects of treatments remain the same. No additional tests or visits are required. Data will be obtained using administrative healthcare databases and medical record review (at a subset of participating locations).",[181,182,27,183,184,185,186,74],"Chronic Kidney Disease Requiring Hemodialysis","End-Stage Kidney Disease (ESKD)","Pragmatic Randomized Controlled Trial","Kidney Disease","Renal Insufficiency, Chronic","Kidney Failure, Chronic",[188,189,190,191,192,193,194],"Nipro Elisio HX","RCT","Dialyzer","Hemodialysis Filter","Super-High Flux Dialyzer","High-Flux Dialyzer","Expanded Hemodialysis","2025-08-22",{"date":197,"type":38},"2025-08-28",{"date":199,"type":38},"2025-08-12",{"date":201,"type":20},"2030-08",{"name":84,"class":85},{"id":204,"slug":205,"hasResults":11,"nctId":206,"briefTitle":207,"officialTitle":208,"acronym":209,"eligibilityCriteria":210,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":211,"targetDuration":4,"studyType":21,"phases":213,"briefSummary":214,"conditions":215,"keywords":216,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":220,"lastUpdatePostDateStruct":221,"startDateStruct":223,"completionDateStruct":225,"leadSponsor":227,"locationsCount":139},"100519187","smart-and-fit-for-kidney-transplantation-100519187","NCT06040281","Smart and Fit for Kidney Transplantation","The Effects of an Interdisciplinary Treatment Approach in ESRD Patients: a Randomised Controlled Trial","S&F4NTx","Inclusion Criteria:\n\n* Patients must be on dialysis\n* Patients ≥ 18 years of age\n* Patients who own a smartphone\n* Patients must be willing to undergo inpatient rehabilitation within the project period\n* signed informed consent and data protection regulation\n\nExclusion Criteria:\n\n* Patients who are not psychologically or physically able to take part in exercise promotion measures and\u002For nutritional counselling as well as psychological offers\n* Patients who have already participated in a similar project",{"count":212,"type":20},200,[150],"This study is a randomised controlled intervention trial for patients with chronic kidney disease who are on the waiting list for a kidney transplantation (n=200). The aim of this study is to test the effectiveness of intensive individual nutritional and exercise support combined with comprehensive rehabilitation before transplantation in comparison to a control group.",[27],[217,218,219],"Transplantation","Prehabilitation","Exercise and Nutritional Support","2025-03-25",{"date":222,"type":38},"2025-03-30",{"date":224,"type":38},"2023-09-18",{"date":226,"type":20},"2026-03-31",{"name":228,"class":85},"University of Erlangen-Nürnberg Medical School",{"id":230,"slug":231,"hasResults":11,"nctId":232,"briefTitle":233,"officialTitle":234,"acronym":4,"eligibilityCriteria":235,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":236,"targetDuration":4,"studyType":69,"phases":4,"briefSummary":237,"conditions":238,"keywords":239,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":245,"lastUpdatePostDateStruct":246,"startDateStruct":248,"completionDateStruct":250,"leadSponsor":252,"locationsCount":139},"100583250","integrating-bia-and-egfr-for-nutritional-status-in-hemodialysis-patients-100583250","NCT06873880","Integrating BIA and eGFR for Nutritional Status in Hemodialysis Patients","Integrating Bioelectrical Impedance Analysis and Estimated Glomerular Filtration Rate: A Novel Approach to Assessment of Nutritional Status of Hemodialysis Patients","Inclusion Criteria:\n\nChronic kidney disease Hemodialysis for at least 6 months\n\nExclusion Criteria:\n\nPregnancy Lactation Major second pathology Pacemaker Recent surgery",{"count":59,"type":20},"This study looks at how measurements of body composition from Bioelectrical Impedance Analysis (BIA) and estimates of kidney function (eGFR) can be applied together to better assess the health of people on hemodialysis. Many dialysis patients struggle with malnutrition, muscle loss, and fluid imbalances, but current assessment methods rely on unsophisticated tests and observations. By combining BIA and eGFR, this study aims to provide a more accurate and non-invasive way to monitor nutrition and overall health, which could lead to better treatment decisions and improved patient outcomes.",[27],[240,241,242,243,244],"Dialysis","Bioelectrical impedance","Nutrition","Body composition","Renal impairment","2025-03-10",{"date":247,"type":38},"2025-03-13",{"date":249,"type":38},"2025-02-10",{"date":251,"type":20},"2025-07-30",{"name":253,"class":85},"University of Tartu",{"id":255,"slug":256,"hasResults":11,"nctId":257,"briefTitle":258,"officialTitle":259,"acronym":4,"eligibilityCriteria":260,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":261,"targetDuration":263,"studyType":69,"phases":4,"briefSummary":264,"conditions":265,"keywords":268,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":272,"lastUpdatePostDateStruct":273,"startDateStruct":275,"completionDateStruct":277,"leadSponsor":278,"locationsCount":139},"100561556","investigation-of-the-validity-reliability-and-responsiveness-of-bety-bq-in-chronic-kidney-disease-on-dialysis-and-kidney-transplantation-100561556","NCT06591702","Investigation of the Validity, Reliability, and Responsiveness of BETY-BQ in Chronic Kidney Disease, on Dialysis, and Kidney Transplantation","Investigation of the Validity, Reliability, and Responsiveness of BETY-Biopsychosocial Questionnaire in Individuals with Chronic Kidney Disease, on Dialysis, and Kidney Transplantation","Individuals with chronic kidney disease:\n\nInclusion Criteria:\n\n* Being diagnosed with chronic kidney disease\n* To be over 18 years old\n* Consent of the participant\n\nExclusion Criteria:\n\n* Acute infection\n* Being diagnosed with cancer\n\nIndividuals on dialysis:\n\nInclusion Criteria:\n\n* Being a dialysis patient\n* To be over 18 years old\n* Consent of the participant\n\nExclusion Criteria:\n\n* Acute infection\n* Being diagnosed with cancer\n\nKidney transplant recipients:\n\nInclusion Criteria:\n\n* To have had a kidney transplant\n* To be over 18 years old\n* Consent of the participant\n\nExclusion Criteria:\n\n* Acute infection\n* Being diagnosed with cancer",{"count":262,"type":20},150,"3 Months","A review of the literature has shown that Chronic Kidney Disease (CKD) is strongly associated with an increasing degree of psychosocial impact, such as depression and anxiety and a decrease in quality of life. Therefore, while determining the psychosocial aspects of the disease gains importance, it is reported that determining and evaluating the biopsychosocial characteristics may facilitate the disease management of individuals. Considering that CKD is associated with various comorbidities, psychosocial features, and symptom burden, it is interpreted that patient-reported outcome measures may support the complex management of these individuals. Routine collection and use of patient-reported outcome measures may provide valuable data for understanding the disease from both individual and community perspectives, with the potential to improve the quality of care and outcomes.\n\nThe Cognitive Exercise Therapy Approach (Bilişsel Egzersiz Terapi Yaklaşımı-BETY) is an innovative exercise model based on physical exercise and an example of a biopsychosocial approach developed for patients with rheumatism. The BETY-Biopsychosocial Questionnaire (BETY-BQ) was created by repeated statistics of improvement characteristics reported by individuals who participated in BETY sessions for many years. The BETY-BQ holistically assesses many biopsychosocial characteristics of the person, such as pain, functionality, mood, sociability, sexuality, and sleep. Therefore, there is a need for scales that assess these symptoms holistically in chronic kidney disease. BETY-BQ can be envisaged as an assessment tool for interdisciplinary healthcare team members who want to evaluate the CKD population, including individuals on dialysis and kidney transplant recipients. Since the BETY-BQ can assess biopsychosocial characteristics quickly and its structure was created with the feedback of individuals with chronic diseases, it aimed to examine its validation in this disease group.\n\nIn this study, which investigators planned to contribute to this field, investigators aimed to investigate the validity, reliability, and sensitivity of BETY-BQ in individuals diagnosed with chronic kidney disease on dialysis and kidney transplantation.",[266,27,267],"Chronic Kidney Disease(CKD)","Kidney Transplantation",[269,270,271,104,267,240],"biopsychosocial model","validity and reliability","BETY-BQ","2024-09-10",{"date":274,"type":38},"2024-09-19",{"date":276,"type":38},"2024-02-21",{"date":82,"type":20},{"name":279,"class":85},"Hacettepe University",{"id":281,"slug":282,"hasResults":11,"nctId":283,"briefTitle":284,"officialTitle":284,"acronym":285,"eligibilityCriteria":286,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":287,"enrollmentInfo":288,"targetDuration":4,"studyType":21,"phases":290,"briefSummary":291,"conditions":292,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":297,"lastUpdatePostDateStruct":298,"startDateStruct":300,"completionDateStruct":302,"leadSponsor":304,"locationsCount":139},"100533417","phase-2-lumasiran-in-hyperoxalaemic-patients-on-haemodialysis-100533417","NCT06225544","Lumasiran in Hyperoxalaemic Patients on Haemodialysis","LHOxH","Inclusion Criteria:\n\n* Male or female patients\n* Aged between 18 and 80 years old at the start of the study.\n* Women of child-bearing potential to consent to either abstinence or the use of contraception during the study period\n* Patients must have capacity to give written, informed consent to participate in the study prior to commencing the study. They must be fully aware of the aims, nature, planned interventions and potential risks of participating in the study. This consent must be obtained by the time of participant inclusion.\n* Established and stable on haemodialysis for at least 2 months\n* Thrice weekly haemodialysis\n* In possession of permanent dialysis access - either arterio-venous fistula (AVF) or graft (AVG) or permanent dialysis catheter\u002Ftunnelled haemodialysis line (THL).\n* ESKD not caused by previously diagnosed primary hyperoxaluria.\n* Mean baseline serum oxalate level of ≥20 μmol\u002FL\n* No recent (within last 2 months) significant changes to regular medications or diet\n\nExclusion Criteria:\n\n* Known diagnosis of PH1, 2 or 3; or a pathological mutation documented to cause primary hyperoxaluria.\n* Established on haemodialysis for less than 2 months.\n* On peritoneal dialysis.\n* Combined haemodialysis and peritoneal dialysis.\n* Temporary or poorly functioning haemodialysis access\n* Pregnancy, planning pregnancy or currently breast feeding.\n* Co-morbidity of an enteric disorder such as Inflammatory Bowel Disease (IBD), short gut syndrome, or a malabsorptive disorder.\n* Decompensated Liver failure.\n* Intercurrent active infection and\u002For antibiotic treatment.\n* Currently on Vitamin C treatment with a daily dose of more than 250mg.\n* Terminal illness and\u002For life expectancy of less than 1 year.\n* Currently relapsed or uncontrolled and symptomatic psychiatric disorder preventing compliance with the study.\n* Participants institutionalised by court or government order.\n* Patients who could be coerced due to dependency on the sponsor, the investigator, the trial sites or test centres.\n* Deranged liver function tests: If alanine aminotransferase (ALT) or aspartate aminotransferase (AST) is more than twice the upper limit","80 Years",{"count":289,"type":20},50,[23],"This study will look at how well a drug that reduced the amount of oxalate in the body works in patients that have kidney disease and need dialysis treatment. People with kidney disease often have higher levels of oxalate in the blood. People with kidney disease are also at higher risk of having heart attacks, heart disease and strokes (these are called cardiovascular diseases). It is thought that high oxalate levels may increase the risk of these diseases. This study will investigate if this medicine can lower the amount of oxalate in the blood of dialysis patients and see if there is any change in the health of their heart. This medicine is already used for people who have high oxalate levels because of a genetic cause and has been used safely for patients on dialysis.\n\nThe study will put the participants randomly into either the group getting the study medicine or the group getting a placebo (this will be a solution of saline water). Neither participants not the doctors will know whether the drug or placebo is given until after the end of the study.\n\nAt the start of the study all the participants will have an echocardiogram (an ultrasound of the heart) and again 6 months later at the end of the study. We will also take blood tests once a month when the participants come for dialysis.",[293,27,294,295,296],"Haemodialysis","Cardiovascular Disease","Cardiovascular Risk Factor","Hyperoxalemia","2024-08-19",{"date":299,"type":38},"2024-08-21",{"date":301,"type":38},"2024-04-14",{"date":303,"type":20},"2025-03-01",{"name":305,"class":85},"Charite University, Berlin, Germany",{"id":307,"slug":308,"hasResults":11,"nctId":309,"briefTitle":310,"officialTitle":311,"acronym":312,"eligibilityCriteria":313,"healthyVolunteers":94,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":314,"targetDuration":4,"studyType":69,"phases":4,"briefSummary":316,"conditions":317,"keywords":318,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":325,"lastUpdatePostDateStruct":326,"startDateStruct":328,"completionDateStruct":330,"leadSponsor":332,"locationsCount":139},"100459705","activation-of-the-contact-system-and-the-immune-system-in-patients-with-chronic-kidney-disease-100459705","NCT05266092","Activation of the Contact System and the Immune System in Patients With Chronic Kidney Disease.","Activation of the Contact System and the Immune System in Patients With Chronic Kidney","AKIM-CKD","Participants with chronic kidney disease undergoing hemodialysis Inclusion criteria\n\n* Age \\>18 years\n* Chronic kidney disease\n* Hemodialysis\n\nExclusion criteria:\n\n\\- Acute kidney disease\n\nParticipants with chronic kidney disease, not in dialysis Inclusion criteria\n\n* Age \\>18 years\n* Chronic kidney disease (eGFR from \\\u003C15 to 44)\n\nExclusion criteria:\n\n* Acute kidney disease\n* Hemodialysis\n* Peritoneal dialysis\n\nParticipants with chronic kidney disease undergoing peritoneal dialysis Inclusion criteria\n\n* Age \\>18 years\n* Chronic kidney disease\n* Peritoneal dialysis\n\nExclusion criteria:\n\n\\- Acute kidney disease\n\nHealthy volunteers Inclusion criteria\n\n* Age \\>18 years\n* Blooddonors\n\nExclusion criteria:\n\n\\- NA",{"count":315,"type":20},400,"Patients with end-stage renal disease undergoing hemodialysis (HD) are burdened with extremely high mortality rates (15% per year) and during the early stage (≤120days) the mortality rate is even higher (27% per year). Cardiovascular complications and bloodstream infections (BSIs) account for the vast majority of deaths in HD patients. In Denmark, BSIs occur in 14% of HD patients per year and is most frequently caused by Staphylococcus aureus (44%). The most frequent infectious complication is endocarditis that has fatal outcomes in ≈50% of the cases. Overall, 10% of HD patients die within 30 days after a positive blood culture for S. aureus. This project aims to answer key questions regarding HD patients' decreased ability to fight S. aureus BSIs and in particular the potential exacerbating effect of HD. We hypothesize that HD patients' blood is significantly compromised by the process of HD, to an extend that lowers immunoactivity against S. aureus. Moreover, we hypothesize, that contact activation promotes the coagulability of blood thus promoting biofilm formation by S. aureus which increases the overall risk of BSI. We will test these hypotheses by collecting blood and analyzing the inflammation and coagulation status in plasma samples from participants before and after HD. We will compare the level of the inflammatory markers in plasma from participants undergoing HD (n=180) to the level in plasma samples from three control groups: healthy volunteers (n=120), participants with renal disease not in dialysis (n=60) and participants undergoing peritoneal dialysis (n=40).",[27],[319,320,321,322,323,74,324],"Contact system","Infection","Innate immune system","Coagulation","Chronic kidney disease","End-stage renal disease","2022-11-14",{"date":327,"type":38},"2022-11-15",{"date":329,"type":38},"2022-04-25",{"date":331,"type":20},"2032-04",{"name":333,"class":85},"Odense University Hospital"]